Phase III LAURA Trial

• Business
• Education
• Financial
• Healthcare
• Industrial
• Investment
• Management
• News
• Pharma & Biotech
• Science
• Security & Safety
• Technology
• United Kingdom

AstraZeneca’s Tagrisso Shows Promise in Phase III LAURA Trial for EGFR-Mutated Lung Cancer

(IN BRIEF) AstraZeneca's Tagrisso (osimertinib) demonstrates significant improvement in progression-free survival (PFS) for patients with unresectable, Stage III EGFR-mutated non-small…